Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01)

Funding Opportunity Number: RFA-DK-14-503 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: Food and NutritionHealthCFDA Number: 93.847Eligible Applicants Others (see text field entitled "Additional Information on Eligibility" for clarification)Agency Name: HHS-NIH11Closing Date: Jul 18, 2014Award Ceiling: $2,500,000Expected Number of Awards: 1Creation Date: Apr 25, 2014Funding Opportunity Description: This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator current awardee of the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Data Coordinating Center (DCC) (AMP T2D-GENES DCC). The AMP T2D-GENES consortium will consist of the DCC as well as participating sites being solicited by the companion FOA. The mission of AMP T2D-GENES is to characterize the genetic variations in human genomic regions that have been putatively associated with type 2 diabetes (T2D) and conduct follow-up functional studies of particular genetic variants. This is a one-time FOA to provide funds to the AMP T2D-GENES DCC to continue the development of the web portal and deposit, aggregate and process the data generated, as part of an ongoing consortium of AMP T2D-GENES investigators as well as T2D-GENES community, for a maximum of five years, contingent on satisfactory performance. To support the conduct of these studies, AMP T2D-GENES DCC will coord...
Source: Grants.gov - Category: Research Tags: Food and Nutrition Health Source Type: funding

Related Links:

Publication date: Available online 12 November 2019Source: Life SciencesAuthor(s): Eman Soliman, Shereen F. Behairy, Nabila N. El-maraghy, Shimaa M. ElshazlyAbstractPeroxisome proliferator-activated receptor γ (PPAR-γ) agonist, pioglitazone, is used clinically to improve the glycemic state in patients with type-2 diabetes mellitus. Independent of its blood glucose-lowering properties, pioglitazone ameliorates different cardiovascular disorders. The aim of the present study was to investigate the effect of pioglitazone on cardiovascular complications of N-nitro-L-arginine methyl ester (L-NAME)-induced hypertensi...
Source: Life Sciences - Category: Biology Source Type: research
Publication date: Available online 12 November 2019Source: Life SciencesAuthor(s): Hauwa’u Yakubu Bako, Mohammed Auwal Ibrahim, Muhammad Sani Isah, Sani IbrahimAbstractAimsChronic inflammation is associated with the production of high levels of proinflammatory cytokines via the JAK-STAT and NF-κB signalling pathways which are known to be inhibited by tofacitinib and aspirin respectively. High levels of these cytokines increase the synthesis of suppressors of cytokines (SOCS), which at high levels inhibit insulin signalling leading to insulin resistance. The effects of tofacitinib and aspirin on the degree of in...
Source: Life Sciences - Category: Biology Source Type: research
Condition:   Type 2 Diabetes Mellitus Interventions:   Drug: DBPR108; Placebo matching sitagliptin;   Drug: Placebo matching DBPR108; Sitagliptin; DBPR108;   Drug: Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108 Sponsor:   CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Takahashi T, Matsuura C, Toyoda K, Suzuki Y, Yamada N, Kobayashi A, Sugai S, Shimoi K Abstract In order to estimate the potential risk of chemicals including drug in patients with type 2 diabetes mellitus (T2DM), we investigated allyl alcohol induced liver injury using SD rats and Spontaneously Diabetic Torii-Leprfa (SDT fatty) rats as a model for human T2DM. The diabetic state is one of the risk factors for chemically induced liver injury because of lower levels of glutathione for detoxification by conjugation with chemicals and environmental pollutants and their reactive metabolites. Allyl alcohol is met...
Source: Journal of Toxicological Sciences - Category: Toxicology Tags: J Toxicol Sci Source Type: research
Insofar as either type 1 diabetes or type 2 diabetes increase the burden of senescent cells, we might say that the condition literally accelerates aging. The accumulation of lingering senescent cells is a contributing cause of aging; these errant cells disrupt tissue function and produce the characteristic profile of chronic inflammation known as inflammaging via a potent mix of secreted molecules and vesicles. Diabetic patients suffer more and worse gum disease, periodontitis, than their healthy peers, and researchers here show that hyperglycemia leads to increased numbers of senescent cells in gum tissue, causing all of ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
TYPE 2 diabetes is a chronic condition that often causes a person ’s blood sugar levels to become too high, and, if left untreated. this can pose deadly health risks. Luckily, certain food items have been shown to help control blood sugar levels, keeping the risks at bay, including a popular herb.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
ConclusionLV mass and diastolic function were not affected after 1  year of metformin treatment in patients with T2DM. However, we observed benefits in terms of reductions in both BMI and LDL-C levels and preservation of renal function.Trial RegistrationUMIN000006504. Registered 7 October 2011.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
Analysis shows consistent renal and cardiovascular benefit when treated with INVOKANA ® even when patients had moderate to severe renal deficiency INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKDData announcemen t comes after recent news of the company’s commercial partnership with Vifor Pharma, leader in nephrology, to jointly commercialize the INVOKANA® DKD indication in the United States
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Publication date: Available online 11 November 2019Source: Prostaglandins &Other Lipid MediatorsAuthor(s): Rupak Shivakoti, Jesmond Dalli, Dileep Kadam, Sanjay Gaikwad, Madhusudan Barthwal, Romain A. Colas, Francesca Mazzacuva, Rahul Lokhande, Sujata Dharmshale, Renu Bharadwaj, Anju Kagal, Neeta Pradhan, Sona Deshmukh, Sachin Atre, Tushar Sahasrabudhe, Arjun Kakrani, Vandana Kulkarni, Swapnil Raskar, Nishi Suryavanshi, Sandy ChonABSTRACTIndividuals with concurrent tuberculosis (TB) and Type 2 diabetes (DM) have a higher risk of adverse outcomes. To better understand potential immunological differences, we utilized a co...
Source: Prostaglandins and Other Lipid Mediators - Category: Lipidology Source Type: research
CONCLUSIONS Hence, we concluded that the overexpression of LINC-PINT may exhibit inhibitory effects on the progression of cardiomyopathy and retinopathy among patients with type 2 diabetes. PMID: 31711064 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
More News: Diabetes | Diabetes Type 2 | Endocrinology | Funding | Genetics | Grants | Health | Nutrition | Partnerships | Research | Study